Quarterly Activities Report and Appendix 4C
Released
Released
Announcement PDF
ASX Announcement
Percheron Therapeutics Limited
ABN 41 095 060 745
ASX: PER | FSE: AWY | US OTC: ATHJY
QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C
Melbourne, Australia – 30 April 2026: Percheron Therapeutics Limited (ASX: PER) (‘the
Company’), an international biotechnology company focused on the development of
novel therapies for oncology and rare diseases, is pleased to provide an update on the
Company’s continuing progress during the quarter ended 31 March 2026.
Key Points
• Non-renounceable entitlement offer raised $2.2 million to progress HMBD-002
program. Eligible shareholders were able to subscribe for two new shares for every
five shares held, at an offer price of $0.005, with the shortfall placed substantially to
new investors.
• HMBD-002 abstracts accepted at premier international scientific conferences
for presentation in April and May 2026. The Company has had an abstract
accepted to the American Association for Cancer Research (AACR) Annual Meeting
in San Diego, CA, which will be held from 17-22 April 2026. A team of researchers
working at QIMR Berghofer Institute in Brisbane, Queensland, have had an abstract
accepted to the American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago, IL, which will be held from 29 May – 2 June 2026.
• Manufacture of new batch of drug substance initiated by Hummingbird
Bioscience. Per contract, the manufacture is the administrative and financial
responsibility of Hummingbird. Drug substance manufacture is scheduled to be
completed in June 2026.
“Our focus since the beginning of the year has been on preparation for the planned
phase II clinical trial of HMBD-002,” commented Percheron CEO, Dr James Garner. “We
have invested significant work in developing the clinical trial design into a detailed
protocol. Our licensor has commenced manufacture of a new batch of drug substance
for use in the trial, which was a provision of the license agreement we executed with
them last year. We have solicited bids from several international contract research
organisations to conduct the study, and we expect to make a final decision on the
chosen partner in the near future. Meanwhile, we are excited to have had the
opportunity to share positive data from the phase I study of HMBD-002 at ASCO, and we
look forward to seeing interesting new preclinical data from our collaboration with QIMR
shared at the ASCO conference in late May.”
Page 2 of 5
$2.2 million raised in Entitlement Offer to progress HMBD-002 program
On 16 March 2026, the Company announced a non-renounceable entitlement offer to
eligible shareholders, under a prospectus filed with the Australian Securities and
Investments Commission. Under the offer, eligible shareholders were able to subscribe
for two new shares for every five shares held, at an offer price of $0.005. Every two
shares issued under the offer were accompanied by one unlisted option, with a strike
price of $0.01, and expiry two years from the date of issue.
In total, 376 eligible holdings subscribed for new shares under the entitlement offer. On
its conclusion, the shortfall was placed to new sophisticated and institutional investors.
Blue Ocean Equities and Cygnet Capital served as joint lead managers to the
transaction. The entitlement offer raised approximately $2.2 million before associated
costs.
The Company intends to apply the funds raised to progress the development of HMBD-
002, which it plans to take into a phase II clinical trial in 2H CY2026, and for working
capital purposes.
HMBD-002 abstracts accepted to international scientific conferences
On 19 February 2026, the Company announced that it had had an abstract accepted for
presentation at the American Association for Cancer Research (AACR) Annual Meeting,
which is scheduled to be held in San Diego, CA, from 17-22 April 2026.
The AACR Annual Meeting is one of the most important scientific conferences in cancer
research. The 2025 meeting attracted more than 22,000 attendees from 85 countries
and territories. In addition to the world’s foremost oncology researchers, the conference
is attended by delegates from pharmaceutical companies and investors and has
become a valuable forum for companies to share new data and results.
Percheron’s abstract principally discussed the results of the recently completed phase I
study of HMBD-002 in patients with advanced cancer. The study was conducted in 48
patients with advanced cancer, at six leading cancer centres in the United States. It
showed HMBD-002 to be generally safe and well-tolerated, both as monotherapy and in
combination with Keytruda (pembrolizumab). A number of patients showed indications
of potential clinical benefit.
On 30 March 2026, the Company announced that a team at QIMR Berghofer, a leading
cancer research institute based in Brisbane, Queensland, had had an abstract accepted
for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting,
which is scheduled to be held in Chicago, IL, from 29 May – 2 June 2026.
The ASCO Annual Meeting is widely regarded as the foremost annual conference for
practising oncologists and clinical researchers, as well as a key event for investors and
pharmaceutical companies. It typically attracts up to 50,000 attendees from over 100
countries and territories. In 2025, more than 7,500 abstracts were submitted to ASCO
Page 3 of 5
for consideration, with only a minority of those being selected for oral or poster
presentations.
QIMR Berghofer is one of the leading independent medical research institutes in
Australia, with a focus on cancer, infectious disease, and mental health. It employs
more than 1,000 staff across a wide range of disciplines, and houses more than 60
laboratories.
The QIMR abstract is the culmination of a research collaboration initiated between
Percheron and QIMR in 2H CY2025 to further explore the biological activity of HMBD-002
and to identify potential biomarkers that may be used in future clinical trials. The project
has been led by Professor Sudha Rao, a leading expert on the use of immunotherapy in
cancer.
Manufacture of clinical trial material initiated
In March 2026, Percheron’s licensor, Hummingbird Bioscience, initiated manufacture of
a new batch of drug substance for use in clinical trials. The material is being produced
under Hummingbird’s oversight and expense at a specialist third-party contract
manufacturer in Asia. As part of the license agreement between Percheron and
Hummingbird signed in June 2025, Hummingbird is obliged to procure the manufacture
of one batch of drug substance on Percheron’s behalf.
The initial phase of manufacture was completed in April 2026, and all relevant
parameters were observed to be within expected limits. Final testing, analysis, and
release of the material is expected to be completed in June 2026. Percheron will then
arrange for the drug substance to be filled into vials for use in clinical trials, with final
production complete in August 2026.
Percheron’s investor hub
Shareholders can sign up to the investor hub using the instructions below:
How to sign up for the Percheron Therapeutics investor hub:
1. Visit percherontx.com/auth/signup
2. Follow the prompts to sign up for our investor hub account
3. Complete your account profile
Page 4 of 5
Financial Position
As noted in the accompanying unaudited quarterly cashflow report (Appendix 4C), the
Company closed the quarter ending 31 March 2026 with a cash balance of $3.10 million,
compared to $4.46 million at the end of the previous quarter. It should be highlighted
that this figure predates the capital raised in April 2026 and is therefore no longer
reflective of the Company’s financial position.
Net cash outflows from operating activities for the quarter were $1.36 million, of which
$0.70 million represented research and development expenditure, with the balance
substantially reflecting the Company’s corporate overheads.
The accompanying unaudited quarterly cashflow report shows a figure of 2.3 quarters
for the Company’s forecast runway. The Company notes that this calculation assumes
steady-state expenditure that is similar quarter-to-quarter. Moreover, as noted
previously, the calculation is made prior to the Company’s recent capital raise and is
therefore no longer reflective of the Company’s financial position.
The Company made payments to related parties of the entity as disclosed in Item 6 of
the Appendix 4C amounting to approximately $0.21 million. These payments represent
salaries, directors' fees, and consulting fees on normal commercial terms.
~ ENDS ~
Page 5 of 5
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology
company focused on the development and commercialisation of novel therapies for oncology
and rare diseases. The company’s lead program is HMBD-002, a monoclonal antibody targeting
the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in
patients with advanced cancer, which has shown the drug to be generally safe and well
tolerated, and Percheron aims to commence further clinical trials in CY2026. For further
information, please see our website at www.PercheronTx.com, or email info@PercheronTx.com.
This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.
Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 1
+ See chapter 19 of the ASX Listing Rules for defined terms.
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Percheron Therapeutics Limited
ABN Quarter ended (“current quarter”)
41 095 060 745 31 March 2026
Consolidated statement of cash flows Current quarter
$A’000
Year to date
(9 months)
$A’000
1. Cash flows from operating activities
- -
1.1 Receipts from customers
1.2 Payments for
(700) (3,178)
(a) research and development
(b) product manufacturing and operating
costs
- -
(c) advertising and marketing (142) (318)
(d) leased assets (6) (24)
(e) staff costs (360) (1,099)
(f) administration and corporate costs (180) (956)
1.3 Dividends received (see note 3) - -
1.4 Interest received 33 146
1.5 Interest and other costs of finance paid - -
1.6 Income taxes paid - -
1.7 Government grants and tax incentives - 1,430
1.8 Other (provide details if material) - -
1.9 Net cash from / (used in) operating
activities
(1,355) (3,999)
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 2
+ See chapter 19 of the ASX Listing Rules for defined terms.
Consolidated statement of cash flows Current quarter
$A’000
Year to date
(9 months)
$A’000
2. Cash flows from investing activities
- -
2.1 Payments to acquire or for:
(a) entities
(b) businesses - -
(c) property, plant and equipment - -
(d) investments - -
(e) intellectual property - (3,068)
(f) other non-current assets - -
2.2 Proceeds from disposal of:
- -
(a) entities
(b) businesses - -
(c) property, plant and equipment - -
(d) investments - -
(e) intellectual property - -
(f) other non-current assets - -
2.3 Cash flows from loans to other entities - -
2.4 Dividends received (see note 3) - -
2.5 Other (provide details if material) - -
2.6 Net cash from / (used in) investing
activities
- (3,068)
3. Cash flows from financing activities
- -
3.1 Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2 Proceeds from issue of convertible debt
securities
- -
3.3 Proceeds from exercise of options - -
3.4 Transaction costs related to issues of
equity securities or convertible debt
securities
- -
3.5 Proceeds from borrowings - -
3.6 Repayment of borrowings - -
3.7 Transaction costs related to loans and
borrowings
- -
3.8 Dividends paid - -
3.9 Other (provide details if material) - -
3.10 Net cash from / (used in) financing
activities
- -
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 3
+ See chapter 19 of the ASX Listing Rules for defined terms.
Consolidated statement of cash flows Current quarter
$A’000
Year to date
(9 months)
$A’000
4. Net increase / (decrease) in cash and
cash equivalents for the period
4,456 10,168
4.1 Cash and cash equivalents at beginning of
period
4.2 Net cash from / (used in) operating
activities (item 1.9 above)
(1,355) (3,999)
4.3 Net cash from / (used in) investing activities
(item 2.6 above)
- (3,068)
4.4 Net cash from / (used in) financing activities
(item 3.10 above)
- -
4.5 Effect of movement in exchange rates on
cash held
- -
4.6 Cash and cash equivalents at end of
period
3,101 3,101
5. Reconciliation of cash and cash
equivalents
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
Current quarter
$A’000
Previous quarter
$A’000
5.1 Bank balances 1,601 606
5.2 Call deposits 1,500 3,850
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5 Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
3,101 4,456
6. Payments to related parties of the entity and their
associates
Current quarter
$A'000
6.1 Aggregate amount of payments to related parties and their
associates included in item 1 1
209
6.2 Aggregate amount of payments to related parties and their
associates included in item 2
-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
1. Director fees and salary payments made to Directors of the Company during 1 January 2026 and 31 March 2026.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 4
+ See chapter 19 of the ASX Listing Rules for defined terms.
7. Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1 Loan facilities - -
7.2 Credit standby arrangements - -
7.3 Other (Corporate Credit Cards) 40 -
7.4 Total financing facilities 40 -
7.5 Unused financing facilities available at quarter end 40
7.6 Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
Credit card facility – American Express
8. Estimated cash available for future operating activities $A’000
8.1 Net cash from / (used in) operating activities (item 1.9) (1,355)
8.2 Cash and cash equivalents at quarter end (item 4.6) 3,101
8.3 Unused finance facilities available at quarter end (item 7.5) 40
8.4 Total available funding (item 8.2 + item 8.3) 3,141
8.5 Estimated quarters of funding available (item 8.4 divided by
item 8.1)
2.3
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: Not applicable
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: Not applicable
8.6.3 Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: Not applicable
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
ASX Listing Rules Appendix 4C (17/07/20) Page 5
+ See chapter 19 of the ASX Listing Rules for defined terms.
Compliance statement
1 This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
Date: 30 April 2026
Authorised by: By the Board of Directors of Percheron Therapeutics Limited
(Name of body or officer authorising release – see note 4)
Notes
1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
Share your feedback
Discover